UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended
	Jul. 31, 2014	Jul. 31, 2013
Operating revenue:
Personalized oncology solutions	$ 341	$ 622
Translational oncology solutions	1,571	2,398
Total operating revenue	1,912	3,020
Costs and operating expenses:
Cost of personalized oncology solutions	757	793
Cost of translational oncology solutions	965	878
Research and development	1,423	402
Sales and marketing	1,034	642
General and administrative	1,462	1,071
Total costs and operating expenses	5,641	3,786
Loss from operations	(3,729)	(766)
Other income (expense):
Change in fair value of warrant liability	155	(1,462)
Other income (expense)	31	(1)
Total other income (expense)	186	(1,463)
Loss before provision for income taxes	(3,543)	(2,229)
Provision for income taxes	5	3
Net loss	$ (3,548)	$ (2,232)
Net loss per common share outstanding, basic and diluted (in dollars per share)	$ (0.05)	$ (0.03)
Weighted average common shares outstanding, basic and diluted (in shares)	66,885,864	66,852,100